Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 13/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | PTGFR | P43088 | 1/20 | 0.34 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.34 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4151015 | 0.88 | PTGER4 (0.37) | PTGER4TBXA2RPTGFRPTGER3PTGER2 | |
| SCHEMBL4167141 | 0.88 | PTGER4 (0.36) | PTGER4TBXA2RPTGFRPTGER3PTGER2 | |
| SCHEMBL13943861 | 0.87 | PTGER4 (0.36) | PTGER4TBXA2RPTGFRPTGER3PTGER2 | |
| SCHEMBL12378107 | 0.87 | KEAP1 (0.34) | PTGER4LMNAHTTSMN1; SMN2TDP1 | |
| SCHEMBL4145609 | 0.86 | CNR2 (0.36) | PTGER4CNR2TBXA2RPTGFRPTGER3 | |
| SCHEMBL14269495 | 0.86 | PTGER4 (0.37) | PTGER4TBXA2RPTGFRPTGER3PTGER2 | |
| SCHEMBL4154626 | 0.85 | COMT (0.40) | CNR2LMNAHTTSMN1; SMN2TDP1 | |
| SCHEMBL4156015 | 0.85 | KDM4E (0.36) | PTGER4LMNAHTTMEN1KMT2A | |
| SCHEMBL13943989 | 0.85 | PTGER4 (0.34) | PTGER4LMNASMN1; SMN2TBXA2RPTGFR | |
| SCHEMBL4142759 | 0.84 | CASP3 (0.35) | PTGER4LMNASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029939-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090029939-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090029939-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | GILEAD SCIENCES, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | GILEAD SCIENCES, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | GILEAD SCIENCES, INC. | 2008-03-27 | — | — | US | disclosed |
| US-7253180-B2 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253180-B2 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253180-B2 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1742642-A2 | PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2007-01-17 | — | — | EP | disclosed |
| US-20060217410-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2006-09-28 | — | — | US | disclosed |
| US-20060116356-A1 | Phosphonate analogs of HIV integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2006-06-01 | — | — | US | disclosed |
| WO-2005117904-A2 | PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| EP-1558613-A2 | PRE-ORGANIZED TRICYCLIC INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20040167124-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157804-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2004-08-12 | — | — | US | disclosed |
| WO-2004035577-A2 | PRE-ORGANIZED TRICYCLIC INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2004035576-A2 | PRE-ORGANIZED TRICYCLIC INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217410-A1 | Pre-organized tricyclic integrase inhibitor compounds | CCNI, INTS6, CCNE1 | PTGER4 873/4885CNR2 2362/4885LMNA 30/4885 |
| US-20040167124-A1 | Pre-organized tricyclic integrase inhibitor compounds | INTS6, INTS9, MUS81 | PTGER4 2295/4885CNR2 2872/4885LMNA 24/4885 |
| US-20040157804-A1 | Pre-organized tricyclic integrase inhibitor compounds | INTS6, INTS9, MUS81 | PTGER4 2295/4885CNR2 2872/4885LMNA 24/4885 |
| US-20090029939-A1 | Pre-organized tricyclic integrase inhibitor compounds | MUS81, CDKL4, INTS6 | PTGER4 940/4885CNR2 2184/4885LMNA 17/4885 |
| US-20060116356-A1 | Phosphonate analogs of HIV integrase inhibitor compounds | TYMP, PNP, PIKFYVE | PTGER4 4254/4885CNR2 4855/4885LMNA 2126/4885 |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | TYMP, PNP, PIKFYVE | PTGER4 4254/4885CNR2 4855/4885LMNA 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.